| Literature DB >> 32838144 |
Gimbada Benny Mwenge1, Daniel Rodenstein1.
Abstract
It was recently described that COVID-19 pneumonia patients had an atypical form of the ARDS syndrome and required gentle ventilation. We report here on benefits of CPAP treatment in a patient with COVID-19 pneumonia. A 63-year-old patient of African origin presented to the emergency room with COVID-19 pneumonia. Fever had started 5 days before her admission. On day 4, rapid clinical deterioration associated to a high respiratory rate and increased oxygen requirements was noted. The patient was working in an intensive care unit and refused to be intubated. Oxygen was administered at a rate of 15 litres per minute via a Boussignac valve, which initially restored normal oxygen saturation, but this treatment was poorly tolerated and the patient withdrew it after 2 h. A CPAP set at a pressure of 8 cm of water (Goodknight®) was then introduced with better tolerance, allowing the patient to wear it almost continuously for more than 38 h. The patient also benefited from the administration of methypredinsolone 40 mg. Concerning tolerance, a substantial advantage was noted for CPAP machine compared to the Boussignac valve with in addition, a clear decrease in respiratory rate. We would like to encourage the use of CPAP, better tolerated for extended hours with lower oxygen flows, in patients with COVID-19 pneumonia, where acute respiratory distress all too often leads to patient intubation and the genesis of deleterious lung lesions. © Springer Nature Switzerland AG 2020.Entities:
Keywords: ARDS; COVID-19 pneumonia; CPAP
Year: 2020 PMID: 32838144 PMCID: PMC7301626 DOI: 10.1007/s42399-020-00349-2
Source DB: PubMed Journal: SN Compr Clin Med ISSN: 2523-8973
Evolution over the days of oxygen saturation, oxygen flow of the mechanical support, and drug treatment
| Time line (days) | CRP (mg/dl) | Oxygen flow (L/min) | Mechanical support or mask | Oxygen saturation (%) (FIO2) | Respiratory rate | Pharmacological therapy |
|---|---|---|---|---|---|---|
| D1 | 22.3 | 2 | Nasal prong | 95 (28%) | 22 | HDX |
| D2 | 6 | Facial mask | 93 (40%) | 28 | HDX | |
| D3 | 47.8 | 6 | Non re-breather face mask | 94 (50%) | 38 | HDX |
| D4 | 73.5 | 15 | 40 | HDX | ||
| 15 | Boussignac valve * | 97* (100%), 92** (50%) | ||||
| D5 | 15 | Boussignac valve* | 97* (100%), 93*** (99%) | 44 | HDX | |
| D6 | 175.2 | 10 | 93 | 44 | AZT | |
| 10 | CPAP 8 cm H2O | 98 | 20 | |||
| D7 | 10 | 90 | ||||
| 8 | CPAP 7 cm H2O | 98 | 20 | HDX | ||
| D8 | 223.2 | 8 | CPAP 7 cm H2O | 98 | 16 | AZT + corticosteroids (Methylprednisolon 40 mg) |
| D9 | 6 | CPAP 7 cm H2O | 98 | 14 | Corticosteroids | |
| D10 | 73.5 | 4 | CPAP 7 cm H2O | 99 | 14 | Corticosteroids |
| D11 | 2 | CPAP 7 cm H2O | 99 (24%) | |||
| D12 | 19.1 | 1 | Nasal prong | 96 | ||
| D13 | 0 | 95 |
*Oxygen saturation measured with Boussignac (tolerated between 2 to 3 h per day, three sessions of 1 h)
**Oxygen saturation measured with oxygen alone (6 l per minute, 50%)
***Oxygen saturation measured with oxygen alone (10 l per minute, 99%)
Fig. 1: This figure shows the patient wearing a face mask. The mask is connected to the Boussignac valve, which is supplied with oxygen through the tube. Note the presence of a Hepa filter to limit the aerosolization of the virus